(NASDAQ:CIGI),(TSX:CIGI), TORONTO and CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) — Colliers (NASDAQ, TSX: CIGI) announced today that its Canadian engineering platform Englobe Corporation (“Englobe”) has acquired Higher Ground Consulting Inc. (“Higher Ground”), a leading engineering consulting firm in Western Canada. Under Colliers' unique partnership model, Higher Ground's management team will become shareholders of Englobe […]

(NASDAQ:CLDX), Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under development Phase 2 EOE study enrollment complete; ongoing enrollment in Phase 2

(NASDAQ:REFR), WOODBURY, N.Y., May 08, 2025 (GLOBE NEWSWIRE) — Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its first quarter of 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. • Who: Joseph M. Harary, President &

(NASDAQ:VTYX), Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance

(NASDAQ:COLL), – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM(R) Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain

(NASDAQ:SHPH), GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of

Serve Robotics Announces First Quarter 2025 Results GlobeNewswire May 08, 2025 Successfully built and deployed 250 new third-generation robots, enhancing operational scale and efficiency Continued geographic expansion into Miami and Dallas metros; Atlanta launch on track First quarter revenue of $440 thousand, a 150% increase versus Q4 2024 Unlocking the value of Serve's software and

Teknova Reports First Quarter 2025 Financial Results GlobeNewswire May 08, 2025 First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze(TM) cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova” or the

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity GlobeNewswire May 08, 2025 Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study highlights superior potency

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results GlobeNewswire May 08, 2025 SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025